Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval

The Microdose | Substack· August 14, 2026

Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval The Microdose | Substack

Read the full story at The Microdose | Substack

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to The Microdose | Substack.

More in Pharmaceutical

Trump Takes Credit for Steepest Prescription Drug Price Decline in Over 60 Years

Recent data from the Bureau of Labor Statistics reveals that year-over-year prescription drug prices fell by 3.1% in July, marking the most significant decline in more than six decades. President Donald Trump has claimed credit for the drop, attributing it to administration agreements with pharmaceutical firms and the launch of the TrumpRX direct-to-consumer platform. This development is critical for the pharmaceutical sector as it highlights the intersection of federal policy, market competition, and shifting cost structures for consumers.

August 15, 2026

What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

The approval of TAUKLARIFY marks a significant development for the pharmaceutical industry's efforts in addressing Alzheimer's disease. This regulatory milestone provides a new diagnostic tool that could potentially streamline the development of tau-targeting therapeutics. For drug developers, this approval signals a shift in the regulatory landscape and offers new opportunities for precision medicine in neurodegenerative research.

August 14, 2026

Prescription drug prices dropped by their biggest margin since 1963

Prescription drug prices in the United States have experienced a 3.1% annual decline, marking the most significant drop for the sector since 1963. This trend comes as medicinal drug prices overall, including over-the-counter products, fell by 2.7% according to recent Bureau of Labor Statistics data. While these figures represent a historic shift for the pharmaceutical market, the savings are being offset for consumers by rising costs in other healthcare segments, such as hospital and physician services.

August 14, 2026

Gilead wins appeals court ruling against overseas drug imports

Gilead Sciences has secured a legal victory in an appeals court ruling concerning the unauthorized importation of its pharmaceutical products from overseas markets. The decision reinforces the company's ability to control its domestic supply chain and protect its intellectual property rights against gray-market imports. This ruling is significant for the pharmaceutical sector as it provides a legal precedent for drug manufacturers seeking to prevent the sale of medications intended for foreign markets within the United States.

August 14, 2026